Clinical Trial Initiation, Executive Appointments, Priced Offering, FDA Clearance, and Upcoming Conferences - Analyst Notes on Cytokinetics, Quintiles, Kindred, Volcano, and Novadaq

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 1, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Cytokinetics, Inc. (NASDAQ: CYTK), Quintiles Transnational Holdings, Inc. (NYSE: Q), Kindred Healthcare, Inc. (NYSE: KND), Volcano Corporation (NASDAQ: VOLC), and Novadaq Technologies Inc. (NASDAQ: NVDQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Cytokinetics, Inc. Analyst Notes 

On March 27, 2014, Cytokinetics, Inc. (Cytokinetics) announced the initiation of an additional Phase I clinical trial of CK-2127107. Cytokinetics informed that the trail, called CY 5012, aims to assess the safety, tolerability, and pharmacokinetics of CK-2127107 following multiple ascending doses in healthy volunteers. The Company informed that the initiation of the clinical trial will result in a $2.0 million milestone payment from Astellas Pharma Inc. (Astellas) to Cytokinetics under the terms of the collaboration between the Companies established in June 2013. Commenting on the trial, Fady Malik, MD, PhD, Senior Vice President of Research and Early Development at Cytokinetics, stated, "This multi-dose clinical trial of CK-2127107 is another in the series of Phase I trials that Cytokinetics is conducting on behalf of the collaboration. These studies along with other Phase II readiness activities will inform the potential progression of CK 2127107 into a Phase II development program focused on non-neuromuscular indications." The full analyst notes on Cytokinetics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/CYTK/report.pdf

--

Quintiles Transnational Holdings, Inc. Analyst Notes 

On March 27, 2014, Quintiles Transnational Holdings, Inc. (Quintiles) announced the appointment of Stella Blackburn, M.B.B.S to the position of Vice President and Global Head of Risk Management for the Company's Real-World & Late Phase Research group. The Company stated that in this role, Dr. Blackburn will lead the group's risk management efforts in North America, European Union, and Asia-Pacific. Quintiles informed that prior to joining the Company, Dr. Blackburn was Risk Management Development and Scientific Lead for the European Medicines AgencyThe full analyst notes on Quintiles Transnational Holdings, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/Q/report.pdf

--

Kindred Healthcare, Inc. Analyst Notes 

On March 26, 2014, Kindred Healthcare, Inc. (Kindred) announced the pricing of its previously announced offering of $500.0 million aggregate principal amount of 6.375% senior notes due 2022 at an issue price of 100%. The Company informed that it anticipates the closing of the offering on April 9, 2014. Kindred added that it intends to use the net proceeds from the sale of the notes and borrowings under certain senior secured credit facilities to redeem and repurchase its outstanding $550 million of existing 8.25% senior notes due 2019. The full analyst notes on Kindred Healthcare, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/KND/report.pdf

--

Volcano Corporation Analyst Notes 

On March 19, 2014, Volcano Corporation (Volcano) announced that it has received FDA clearance for its proprietary instant wave-Free Ratio™ or iFR® Modality. The Company informed that the iFR Modality is currently installed on over 300 systems around the world, mainly in Europe and Japan. Volcano stated that the FDA Clearance allows 90% of the Company's worldwide installed base of multi-modality systems to be upgraded. According to Volcano, the iFR® Modality is used most efficiently with the Company's recently-introduced Verrata™ Pressure Guide Wire. Commenting on the clearance, Joe Burnett, Executive Vice President and General Manager of the FM Business at Volcano, stated, "We are extremely excited that both the iFR Modality and Verrata can now be made available to clinicians here in the United States, as the two tools are designed to be used together. In Europe, where we are now seeing how physicians use the two technologies alongside FFR, the feedback has been very positive." The full analyst notes on Volcano Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04012014/VOLC/report.pdf

--

Novadaq Technologies, Inc. Analyst Notes 

On March 25, 2014, Novadaq Technologies, Inc. (Novadaq) announced that it will be participating at the 13th Annual Needham Healthcare Conference. The Company stated that its Vice President of Corporate Development & Investor Relations, David Martin, is scheduled to present Novadaq's corporate overview on April 8, 2014 at 4:20 p.m. ET at the Westin Grand Central Hotel in New York. Novadaq added that the presentation will be webcast live and will also be archived for 90 days on the Company website. The full analyst notes on Novadaq Technologies, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/NVDQ/report.pdf

--


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

 

SOURCE Analysts Review

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.